argenx SEARGX -0.60%73 Return-on-Tangible-Equity is 20.76% as of Mar. 2026. GuruFocus rates ARGX with a GF Score™ of 73/100 and a GF Value™ of $1,407.83 (Significantly Undervalued). The stock has 5 warning signs investors should review. Among 1,196 Biotechnology companies, argenx SE ranks better than 91.89% on this metric.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. argenx SE's annualized net income for the quarter that ended in Mar. 2026 was $1,464 Mil. argenx SE's average shareholder tangible equity for the quarter that ended in Mar. 2026 was $7,051 Mil. Therefore, argenx SE's annualized Return-on-Tangible-Equity for the quarter that ended in Mar. 2026 was 20.76%.
The historical rank and industry rank for argenx SE's Return-on-Tangible-Equity or its related term are showing as below:
ARGX'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: -44.26 Med: -17.96 Max: 23.68
Current: 23.68
During the past 13 years, argenx SE's highest Return-on-Tangible-Equity was 23.68%. The lowest was -44.26%. And the median was -17.96%.
ARGX's Return-on-Tangible-Equity is ranked better than 91.89% of 1196
companies
in the Biotechnology industry
Industry Median: -42.19
vs ARGX: 23.68
argenx SE (NAS:ARGX) Return-on-Tangible-Equity Explanation
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
argenx SE Return-on-Tangible-Equity Related Terms
argenx SE Return-on-Tangible-Equity Historical Data
* Premium members only.
The historical data trend for argenx SE's Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ARGX vs VRTX, REGN, ALNY: Return-on-Tangible-Equity Comparison
For the Biotechnology subindustry, argenx SE's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
argenx SE Return-on-Tangible-Equity vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, argenx SE's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where argenx SE's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Mar. 2026) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of 20.76% mean?
argenx SE (ARGX) has a Return-on-Tangible-Equity of 20.76% as of Mar. 2026. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on argenx SE and its competitors. According to the industry distribution chart, argenx SE ranks #97 out of 1196 companies in the Biotechnology industry, placing it in the top 8.1%.
Is argenx SE's Return-on-Tangible-Equity too high?
argenx SE's current Return-on-Tangible-Equity is 20.76%. Based on the distribution chart, argenx SE ranks #97 out of 1196 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, argenx SE has a GF Score™ of 73/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does argenx SE's Return-on-Tangible-Equity compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, argenx SE ranks #97 out of 1196 companies for Return-on-Tangible-Equity. This places argenx SE in the top 8% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Biotechnology company?
A good Return-on-Tangible-Equity depends on the Biotechnology industry context. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on argenx SE and its competitors. argenx SE's current Return-on-Tangible-Equity is 20.76%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is argenx SE stock overvalued right now?
Based on GuruFocus' analysis, argenx SE (ARGX) is currently considered Significantly Undervalued. The stock's GF Value™ is $1,407.83, compared to a current price of $909.49 — trading 35.4% below its estimated fair value. The current Return-on-Tangible-Equity is 20.76%. argenx SE's overall GF Score™ is 73/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For argenx SE (ARGX), the current Return-on-Tangible-Equity is 20.76% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is argenx SE (ARGX) Overvalued in 2026?
Based on GuruFocus' analysis, argenx SE stock appears to be undervalued.
The current stock price of $909.49 is trading 35.4% below its estimated GF Value™ of $1,407.83.
GuruFocus considers argenx SE to be Significantly Undervalued.
Key valuation signals for ARGX:
Return-on-Tangible-Equity: 20.76%
GF Value™: $1,407.83 vs. price of $909.49 (35.4% below fair value)
No single metric tells the full story. See the ARGX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Argenx is a Dutch biopharmaceutical company focused on developing antibody-based therapies for rare autoimmune diseases. The company's lead product, Vyvgart (efgartigimod), was approved by the FDA in December 2021 for the treatment of generalized myasthenia gravis (gMG). In 2022, Argenx also received FDA approval for Vyvgart Hytrulo, a subcutaneous formulation of Vyvgart, offering a more convenient option compared with Vyvgart's intravenous administration. In 2024, the FDA approved Vyvgart Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy, a rare immune-mediated neuromuscular disorder of the peripheral nervous system. Argenx is focused on innovation and developing its pipeline for treatments such as primary immune thrombocytopenia, thyroid eye disease, and Sjogren's Disease.
73GF Score
Get the complete analysis for ARGX
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ARGX has been successfully added to your 
